Can Natriuretic Peptides be Used to Guide Therapy?
Over the last 15 years, the hypothesis that intensified treatment directed at reducing natriuretic peptide (NP) concentrations may improve the outcomes of patients with heart failure (HF) has been scrutinized in several prospective clinical trials, with conflicting results. Collectively, however, the data suggest that NP concentrations may be useful in guiding HF management and improving HF-related morbidity and mortality. In this review, we summarize the existing data investigating the use of NPs as targets for outpatient HF therapy. We focus on the information gathered in randomized clinical trials and comprehensive meta-analyses, and also on the recommendations of international guidelines (primarily guidelines from the European Society of Cardiology and the American College of Cardiology/American Heart Association). Although the results for this approach are promising overall, additional well-designed prospective randomized controlled trials (e.g., the GUIDE-IT trial) are necessary to confirm or refute the utility of NP-guided outpatient HF management.
Heart Failure Clinic, Cardiology Service, Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain; Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
Antoni
A
Bayes-Genis
Heart Failure Clinic, Cardiology Service, Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain; Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
Josep
J
Lupón
Department of Medicine, Mayo Clinic and Foundation , Rochester, MN, USA.
Allan S
AS
Jaffe
BNP; NT-proBNP; guided-therapy; natriuretic peptides
Am Heart J. 2013 Jun;165(6):995-9
23708172
Am Heart J. 2006 Nov;152(5):828-34
17070141
Eur Heart J. 2013 Feb;34(6):432-42
22875412
Clin Chem. 2009 Jan;55(1):78-84
19028821
Congest Heart Fail. 2005 Sep-Oct;11(5):248-53; quiz 254-5
16230866
J Am Coll Cardiol. 2010 Feb 16;55(7):645-53
20170790
JACC Heart Fail. 2014 Oct;2(5):457-65
25194287
Arch Intern Med. 2010 Mar 22;170(6):507-14
20308637
Circulation. 2015 Jan 6;131(1):54-61
25403646
JAMA. 2009 Jan 28;301(4):383-92
19176440
Eur J Heart Fail. 2011 Oct;13(10):1096-103
21715446
J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239
23747642
Mayo Clin Proc. 2013 Mar;88(3):234-43
23384388
Eur J Heart Fail. 2012 Aug;14(8):803-69
22828712
J Card Fail. 2011 Aug;17(8):613-21
21807321
N Engl J Med. 2014 Sep 11;371(11):993-1004
25176015
J Am Coll Cardiol. 2009 Dec 29;55(1):53-60
20117364
J Am Coll Cardiol. 2010 Dec 14;56(25):2090-100
21144969
Am Heart J. 2009 Sep;158(3):422-30
19699866
PLoS One. 2013;8(3):e58287
23472172
J Am Coll Cardiol. 2007 Apr 24;49(16):1733-9
17448376
J Am Coll Cardiol. 2011 Oct 25;58(18):1881-9
22018299
Med Clin (Barc). 2010 Oct 2;135(10):435-40
20673678
Lancet. 2000 Apr 1;355(9210):1126-30
10791374
Eur J Heart Fail. 2010 Dec;12(12):1300-8
20876734